Arcturus Therapeutics IPO
Arcturus Therapeutics is a messenger RNA medicines company focused on developing treatments for liver and respiratory diseases. The company's proprietary RNA platform and its work on both therapeutics and vaccines have attracted investor interest, particularly following increased attention to mRNA technology.
What We Know
Arcturus Therapeutics has been publicly traded since 2013 when it completed its initial public offering. The company trades on NASDAQ under the ticker symbol 'ARCT' and has been developing its mRNA platform for over a decade. The company gained increased attention during the COVID-19 pandemic due to its mRNA vaccine development efforts, though its broader pipeline focuses on liver diseases and other therapeutic applications. Like many biotech stocks, Arcturus has experienced significant volatility, particularly around clinical trial results and partnership announcements related to its mRNA platform technologies.
Frequently Asked Questions
Has Arcturus Therapeutics had an IPO?
Yes, Arcturus Therapeutics completed its IPO in 2013 and has been publicly traded for over a decade. The mRNA medicines company trades on NASDAQ under ticker 'ARCT'.
When is the Arcturus Therapeutics IPO date?
Arcturus Therapeutics already went public in 2013, so there is no upcoming IPO. The company has been trading publicly on NASDAQ for many years.
How can I buy Arcturus Therapeutics stock?
You can purchase Arcturus Therapeutics stock through any major brokerage since it trades on NASDAQ under ticker 'ARCT'. Shares are available for trading during regular market hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts